Immunoregulation by members of the TGFβ superfamily

Nature Reviews Immunology

Volumn 16, Issue 12, 2016, Pages 723-740

  Chen, Wanjun ^a   Ten Dijke, Peter ^b  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; OSTEOGENIC PROTEIN 1; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD5 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; ACTIVIN; BONE MORPHOGENETIC PROTEIN;

AUTOIMMUNITY; B LYMPHOCYTE; CELL ACTIVATION; CELL FUNCTION; DENDRITIC CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INFECTION; INFLAMMATION; MACROPHAGE; MAST CELL; MONOCYTE; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR IMMUNITY; ANIMAL; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; HOMEOSTASIS; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; MULTIGENE FAMILY; NEOPLASMS;

ACTIVINS; ANIMALS; BONE MORPHOGENETIC PROTEINS; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMANS; IMMUNE SYSTEM; IMMUNOMODULATION; INFLAMMATION; MULTIGENE FAMILY; NEOPLASMS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84997108006     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri.2016.112     Document Type: Review

References (205)

1. Feng, X. H. & Derynck, R. Specificity and versatility in TGF-β signaling through Smads. Annu. Rev. Cell Dev. Biol. 21, 659-693 (2005).
2. Wu, M. Y. & Hill, C. S. TGF-β superfamily signaling in embryonic development and homeostasis. Dev. Cell 16, 329-343 (2009).
3. Chen, W. & Wahl, S. M. TGF-β: receptors, signaling pathways and autoimmunity. Curr. Dir. Autoimmun. 5, 62-91 (2002).
4. Letterio, J. J. & Roberts, A. B. Regulation of immune responses by TGF-β. Annu. Rev. Immunol. 16, 137-161 (1998).
5. Li, M. O. & Flavell, R. A. TGF-β: a master of all T cell trades. Cell 134, 392-404 (2008).
6. Travis, M. A. & Sheppard, D. TGF-β activation and function in immunity. Annu. Rev. Immunol. 32, 51-82 (2014).
7. Akhurst, R. J. & Padgett, R. W. Matters of context guide future research in TGFβ superfamily signaling. Sci. Signal. 8, re10 (2015).
8. Massague, J. TGFβ signalling in context. Nat. Rev. Mol. Cell Biol. 13, 616-630 (2012).
9. Mu, Y., Gudey, S. K. & Landstrom, M. Non-Smad signaling pathways. Cell Tissue Res. 347, 11-20 (2012).
10. + regulatory T cells. J. Mol. Cell Biol. 2, 30-36 (2010).
11. + regulatory T cells: TGF-β matters. Eur. J. Immunol. 45, 958-965 (2015).
12. + regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev. 14, 85-89 (2003).
13. Flavell, R. A., Sanjabi, S., Wrzesinski, S. H. & Licona- Limon, P. The polarization of immune cells in the tumour environment by TGFβ. Nat. Rev. Immunol. 10, 554-567 (2010).
14. Gorelik, L. & Flavell, R. A. Transforming growth factor-β in T-cell biology. Nat. Rev. Immunol. 2, 46-53 (2002).
15. Rubtsov, Y. P. & Rudensky, A. Y. TGFβ signalling in control of T-cell-mediated self-reactivity. Nat. Rev. Immunol. 7, 443-453 (2007).
16. Tu, E., Chia, P. Z. & Chen, W. TGFβ in T cell biology and tumor immunity: angel or devil? Cytokine Growth Factor Rev. 25, 423-435 (2014).
17. Datto, M. B. et al. Targeted disruption of Smad3 reveals an essential role in transforming growth factor β-mediated signal transduction. Mol. Cell. Biol. 19, 2495-2504 (1999).
18. + intestinal intraepithelial lymphocytes by TGF-β. Nat. Immunol. 12, 312-319 (2011).
19. 1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl Acad. Sci. USA 90, 770-774 (1993).
20. Li, M. O., Sanjabi, S. & Flavell, R. A. Transforming growth factor-β controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 25, 455-471 (2006).
21. + regulatory T cells. Nat. Immunol. 9, 632-640 (2008).
22. Marie, J. C., Liggitt, D. & Rudensky, A. Y. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-β receptor. Immunity 25, 441-454 (2006).
23. Shull, M. M. et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 359, 693-699 (1992).
24. Takimoto, T. et al. Smad2 and Smad3 are redundantly essential for the TGF-β-mediated regulation of regulatory T plasticity and Th1 development. J. Immunol. 185, 842-855 (2010).
25. Yang, X. et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-β. EMBO J. 18, 1280-1291 (1999).
26. + regulatory T cells. Crit. Rev. Immunol. 31, 53-60 (2011).
27. Phillips, D. J., de Kretser, D. M. & Hedger, M. P. Activin and related proteins in inflammation: not just interested bystanders. Cytokine Growth Factor Rev. 20, 153-164 (2009).
28. Seeger, P., Musso, T. & Sozzani, S. The TGF-β superfamily in dendritic cell biology. Cytokine Growth Factor Rev. 26, 647-657 (2015).
29. Martínez, V. G. et al. The canonical BMP signaling pathway is involved in human monocyte-derived dendritic cell maturation. Immunol. Cell Biol. 89, 610-618 (2011).
30. + T cell activation and homeostasis. PLoS ONE 10, e0131453 (2015).
31. Takabayashi, H. et al. Anti-inflammatory activity of bone morphogenetic protein signaling pathways in stomachs of mice. Gastroenterology 147, 396-406 (2014).
32. Miyazono, K. et al. A role of the latent TGF-p 1 -binding protein in the assembly and secretion of TGF-p 1. EMBO J. 10, 1091-1101 (1991).
33. Wang, R. et al. GARP regulates the bioavailability and activation of TGFp. Mol. Biol. Cell 23, 1129-1139 (2012).
34. Robertson, I. B. & Rifkin, D. B. Regulation of the bioavailability of TGF-p and TGF-p-related proteins. Cold Spring Harb. Perspect. Biol. 8, a021907 (2016).
35. Hedger, M. P. & de Kretser, D. M. The activins and their binding protein, follistatin - diagnostic and therapeutic targets in inflammatory disease and fibrosis. Cytokine Growth Factor Rev. 24, 285-295 (2013).
36. Wang, X., Harris, R. E., Bayston, L. J. & Ashe, H. L. Type IV collagens regulate BMP signalling in Drosophila. Nature 455, 72-77 (2008).
37. Brazil, D. P., Church, R. H., Surae, S., Godson, C. & Martin, F BMP signalling: agony and antagony in the family. Trends Cell Biol. 25, 249-264 (2015).
38. Cheifetz, S. et al. Distinct transforming growth factor-]] (TGF-p) receptor subsets as determinants of cellular responsiveness to three TGF-p isoforms. J. Biol. Chem. 265, 20533-20538 (1990).
39. Corradini, E., Babitt, J. L. & Lin, H. Y. The RGM/ DRAGON family of BMP co-receptors. Cytokine Growth Factor Rev. 20, 389-398 (2009).
40. Itoh, S. & ten Dijke, P. Negative regulation of TGF-p receptor/Smad signal transduction. Curr. Opin. Cell Biol. 19, 176-184 (2007).
41. Goumans, M. J. et al. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFp/ ALK5 signaling. Mol. Cell 12, 817-828 (2003).
42. Daly, A. C, Randall, R. A. & Hill, C. S. Transforming growth factor p-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage- independent growth. Mol. Cell. Biol. 28, 6889-6902 (2008).
43. Labbe, E., Silvestri, C, Hoodless, P. A., Wrana, J. L & Attisano, L. Smad2 and Smad3 positively and negatively regulate TGFp-dependent transcription through the forkhead DNA-binding protein FAST2. Mol. Cell 2, 109-120 (1998).
44. Tsukamoto, S. et al. Smad9 is a new type of transcriptional regulator in bone morphogenetic protein signaling. Sci. Rep. 4, 7596 (2014).
45. He, W et al. Hematopoiesis controlled by distinct TIF1 y and Smad4 branches of the TGFp pathway Cell 125, 929-941 (2006).
46. Sorrentino, A. et al. The type I TGF-p receptor engages TRAF6 to activate TAK1 in a receptor kinase- independent manner. Nat. Cell Biol. 10, 1199-1207 (2008).
47. Papadimitriou, E., Kardassis, D., Moustakas, A. & Stournaras, C. TGFp-induced early activation of the small GTPase RhoA is Smad2/3-independent and involves Src and the guanine nucleotide exchange factor Vav2. Cell Physiol. Biochem. 28, 229-238 (2011).
48. Lee, M. K. et al. TGF-p activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J. 26, 3957-3967 (2007).
49. Aleman-Muench, G. R. & Soldevila, G. When versatility matters: activins/inhibins as key regulators of immunity. Immunol. Cell Biol. 90, 137-148 (2012).
50. Mather, J. P., Roberts, P. E. & Krummen, L. A. Follistatin modulates activin activity in a cell- and tissue-specific manner. Endocrinology 132, 2732-2734 (1993).
51. Jones, K. L. et al. Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc. Natl Acad. Sci. USA 104, 16239-16244 (2007).
52. 3 stimulates activin A production to fine-tune osteoblast-induced mineralization. J. Cell. Physiol. 228, 2167-2174 (2013).
53. Yu, J. et al. Induced expression of the new cytokine, activin A, in human monocytes: inhibition by glucocorticoids and retinoic acid. Immunology 88, 368-374 (1996).
54. Eramaa, M., Hurme, M., Stenman, U. H. & Ritvos, O. Activin A/erythroid differentiation factor is induced during human monocyte activation. J. Exp. Med. 176, 1449-1452 (1992).
55. Abe, M. et al. Potent induction of activin A secretion from monocytes and bone marrow stromal fibroblasts by cognate interaction with activated T cells. J. Leukoc. Biol. 72, 347-352 (2002).
56. Winnall, W. R., Muir, J. A. & Hedger, M. P. Differential responses of epithelial Sertoli cells of the rat testis to Toll-like receptor 2 and 4 ligands: implications for studies of testicular inflammation using bacterial lipopolysaccharides. Innate Immun. 17, 123-136 (2011).
57. Wilson, K. M., Smith, A. I. & Phillips, D. J. Stimulatory effects of lipopolysaccharide on endothelial cell activin and follistatin. Mol. Cell. Endocrinol. 253, 30-35 (2006).
58. Lee, J. K. et al. Serum activin-A as a predictive and prognostic marker in critically ill patients with sepsis. Respirology 21, 891-897 (2016).
59. Ogawa, K. & Funaba, M. Activin in humoral immune responses. Vitam. Horm. 85, 235-253 (2011).
60. Miron, V. E. et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat. Neurosci. 16, 1211-1218 (2013).
61. Scutera, S. et al. Production and function of activin A in human dendritic cells. Eur. Cytokine Netw. 19, 60-68 (2008).
62. Seeger, P. et al. Activin A as a mediator of NK-dendritic cell functional interactions. J. Immunol. 192, 1241-1248 (2014).
63. Robson, N. C. et al. Activin-A attenuates several human natural killer cell functions. Blood 11 3, 3218-3225 (2009).
64. Robson, N. C. et al. Activin-A: a novel dendritic cell- derived cytokine that potently attenuates CD40 ligand-specific cytokine and chemokine production. Blood 111, 2733-2743 (2008).
65. Salogni, L. et al. Activin A induces dendritic cell migration through the polarized release of CXC chemokine ligands 12 and 14. Blood 11 3, 5848-5856 (2009).
66. Cho, S. H. et al. Regulation of activin A expression in mast cells and asthma: its effect on the proliferation of human airway smooth muscle cells. J. Immunol. 170, 4045-4052 (2003).
67. Funaba, M., Ikeda, T., Ogawa, K. & Abe, M. Calcium- regulated expression of activin A in RBL-2H3 mast cells. Cell Signal. 15, 605-613 (2003).
68. Funaba, M., Ikeda, T., Ogawa, K., Murakami, M. & Abe, M. Role of activin A in murine mast cells: modulation of cell growth, differentiation, and migration. J. Leukoc. Biol. 73, 793-801 (2003).
69. Karagiannidis, C. et al. Activin A is an acute allergen- responsive cytokine and provides a link to TGF-β- mediated airway remodeling in asthma. J. Allergy Clin. Immunol. 11 7, 111-118 (2006).
70. Semitekolou, M. et al. Activin-A induces regulatory T cells that suppress T helper cell immune responses and protect from allergic airway disease. J. Exp. Med. 206, 1769-1785 (2009).
71. Hardy, C. L. et al. Interleukin-13 regulates secretion of the tumor growth factor-β superfamily cytokine activin A in allergic airway inflammation. Am. J. Respir. Cell Mol. Biol. 42, 667-675 (2010).
72. Zipori, D. & Barda-Saad, M. Role of activin A in negative regulation of normal and tumor B lymphocytes. J. Leukoc. Biol. 69, 867-873 (2001).
73. Yamashita, N. et al. Effects of activin A on IgE synthesis and cytokine production by human peripheral mononuclear cells. Clin. Exp. Immunol. 94, 214-219 (1993).
74. Ogawa, K., Funaba, M. & Tsujimoto, M. A dual role of activin A in regulating immunoglobulin production of B cells. J. Leukoc. Biol. 83, 1451-1458 (2008).
75. Lee, H. J. & Kim, P. H. Further characterization of activin A-induced IgA response in murine B lymphocytes. Immune Netw. 9, 133-137 (2009).
76. Licona, P., Chimal-Monroy, J. & Soldevila, G. Inhibins are the major activin ligands expressed during early thymocyte development. Dev. Dyn. 235, 1124-1132 (2006).
77. Rosendahl, A., Speletas, M., Leandersson, K., Ivars, F. & Sideras, P. Transforming growth factor-β- and Activin-Smad signaling pathways are activated at distinct maturation stages of the thymopoeisis. Int. Immunol. 15, 1401-1414 (2003).
78. Licona-Limon, P. et al. Activins and inhibins: novel regulators of thymocyte development. Biochem. Biophys. Res. Commun. 381, 229-235 (2009).
79. Ogawa, K., Funaba, M., Chen, Y. & Tsujimoto, M. Activin A functions as a Th2 cytokine in the promotion of the alternative activation of macrophages. J. Immunol. 177, 6787-6794 (2006).
80. H9 cell- mediated pulmonary allergic pathology. J. Allergy Clin. Immunol. 129, 1000-1010 (2012).
81. + induced regulatory T cells. J. Immunol. 182, 4633-4640 (2009).
82. Pluchino, S. et al. Immune regulatory neural stem/ precursor cells protect from central nervous system autoimmunity by restraining dendritic cell function. PLoS ONE 4, e5959 (2009).
83. Yasmin, N. et al. Identification of bone morphogenetic protein 7 (BMP7) as an instructive factor for human epidermal Langerhans cell differentiation. J. Exp. Med. 210, 2597-2610 (2013).
84. + progenitors in serum-free medium. Adv. Exp. Med. Biol. 417, 161-165 (1997).
85. Borkowski, T. A., Letterio, J. J., Farr, A. G. & Udey, M. C. A role for endogenous transforming growth factor β1 in Langerhans cell biology: the skin of transforming growth factor β1 null mice is devoid of epidermal Langerhans cells. J. Exp. Med. 184, 2417-2422 (1996).
86. Li, A. G., Lu, S. L., Han, G., Hoot, K. E. & Wang, X. J. Role of TGFβ in skin inflammation and carcinogenesis. Mol. Carcinog. 45, 389-396 (2006).
87. Hong, J. H. et al. Effect of bone morphogenetic protein-6 on macrophages. Immunology 128, e442-e450 (2009).
88. Kwon, S. J., Lee, G. T., Lee, J. H., Kim, W. J. & Kim, I. Y. Bone morphogenetic protein-6 induces the expression of inducible nitric oxide synthase in macrophages. Immunology 128, e758-e765 (2009).
89. Lee, G. T. et al. Induction of interleukin-6 expression by bone morphogenetic protein-6 in macrophages requires both SMAD and p38 signaling pathways. J. Biol. Chem. 285, 39401-39408 (2010).
90. Lee, J. H. et al. BMP-6 in renal cell carcinoma promotes tumor proliferation through IL-10-dependent M2 polarization of tumor-associated macrophages. Cancer Res. 73, 3604-3614 (2013).
91. Owens, P. et al. Inhibition of BMP signaling suppresses metastasis in mammary cancer. Oncogene 34, 2437-2449 (2015).
92. Muller, P. A. et al. Crosstalk between muscularis macrophages and enteric neurons regulates gastrointestinal motility. Cell 158, 300-313 (2014).
93. Hidalgo, L. et al. Expression of BMPRIA on human thymic NK cell precursors: role of BMP signaling in intrathymic NK cell development. Blood 119, 1861-1871 (2012).
94. Gascoyne, D. M. et al. The basic leucine zipper transcription factor E4BP4 is essential for natural killer cell development. Nat. Immunol. 10, 1118-1124 (2009).
95. Kamizono, S. et al. Nfil3/E4bp4 is required for the development and maturation of NK cells in vivo. J. Exp. Med. 206, 2977-2986 (2009).
96. Heemskerk, M. H. et al. Inhibition of T cell and promotion of natural killer cell development by the dominant negative helix loop helix factor Id3. J. Exp. Med. 186, 1597-1602 (1997).
97. Robson, N. C. et al. Optimal effector functions in human natural killer cells rely upon autocrine bone morphogenetic protein signaling. Cancer Res. 74, 5019-5031 (2014).
98. Cortez, V. S. et al. Transforming growth factor-β signaling guides the differentiation of innate lymphoid cells in salivary glands. Immunity 44, 1127-1139 (2016).
99. Denney, L. et al. Pulmonary epithelial cell-derived cytokine TGF-β1 is a critical cofactor for enhanced innate lymphoid cell function. Immunity 43, 945-958 (2015).
100. Huse, K. et al. Bone morphogenetic proteins inhibit CD40L/IL-21-induced Ig production in human B cells: differential effects of BMP-6 and BMP-7. Eur. J. Immunol. 41, 3135-3145 (2011).
101. Jurberg, A. D., Vasconcelos-Fontes, L. & Cotta-de-Almeida, V. A. Tale from TGF-β superfamily for thymus ontogeny and function. Front. Immunol. 6, 442 (2015).
102. Bleul, C. C. & Boehm, T. BMP signaling is required for normal thymus development. J. Immunol. 175, 5213-5221 (2005).
103. Gordon, J., Patel, S. R., Mishina, Y. & Manley, N. R. Evidence for an early role for BMP4 signaling in thymus and parathyroid morphogenesis. Dev. Biol. 339, 141-154 (2010).
104. Hager-Theodorides, A. L. et al. Bone morphogenetic protein 2/4 signaling regulates early thymocyte differentiation. J. Immunol. 169, 5496-5504 (2002).
105. Tsai, P. T., Lee, R. A. & Wu, H. BMP4 acts upstream of FGF in modulating thymic stroma and regulating thymopoiesis. Blood 102, 3947-3953 (2003).
106. Yoshioka, Y., Ono, M., Osaki, M., Konishi, I. & Sakaguchi, S. Differential effects of inhibition of bone morphogenic protein (BMP) signalling on T-cell activation and differentiation. Eur. J. Immunol. 42, 749-759 (2012).
107. Sivertsen, E. A. et al. Inhibitory effects and target genes of bone morphogenetic protein 6 in Jurkat TAg cells. Eur. J. Immunol. 37, 2937-2948 (2007).
108. Varas, A. et al. Interplay between BMP4 and IL-7 in human intrathymic precursor cells. Cell Cycle 8, 4119-4126 (2009).
109. Antsiferova, M. & Werner, S. The bright and the dark sides of activin in wound healing and cancer. J. Cell Sci. 125, 3929-3937 (2012).
110. Antsiferova, M. et al. Activin enhances skin tumourigenesis and malignant progression by inducing a pro-tumourigenic immune cell response. Nat. Commun. 2, 576 (2011).
111. Davis, H., Raja, E., Miyazono, K., Tsubakihara, Y. & Moustakas, A. Mechanisms of action of bone morphogenetic proteins in cancer. Cytokine Growth Factor Rev. 27, 81-92 (2015).
112. Wakefield, L. M. & Hill, C. S. Beyond TGFβ: roles of other TGFβ superfamily members in cancer. Nat. Rev. Cancer 13, 328-341 (2013).
113. Martínez, V. G. et al. Autocrine activation of canonical BMP signaling regulates PD-L1 and PD-L2 expression in human dendritic cells. Eur. J. Immunol. 44, 1031-1038 (2014).
114. + Treg. Eur. J. Immunol. 40, 142-152 (2010).
115. Hardy, C. L., Rolland, J. M. & O'Hehir, R. E. The immunoregulatory and fibrotic roles of activin A in allergic asthma. Clin. Exp. Allergy 45, 1510-1522 (2015).
116. Soler Palacios, B. et al. Macrophages from the synovium of active rheumatoid arthritis exhibit an activin A-dependent pro-inflammatory profile. J. Pathol. 235, 515-526 (2015).
117. Ota, F. et al. Activin A induces cell proliferation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Rheum. 48, 2442-2449 (2003).
118. Dong, F. & He, X. Activin A: a potential therapeutic target for characterizing and stopping joint pain early in rheumatoid arthritis patients. Inflammation 37, 170-176 (2014).
119. Yu, E. W., Dolter, K. E., Shao, L. E. & Yu, J. Suppression of IL-6 biological activities by activin A and implications for inflammatory arthropathies. Clin. Exp. Immunol. 112, 126-132 (1998).
120. Torricell, M. et al. High levels of maternal serum IL-17 and activin A in pregnant women affected by systemic lupus erythematosus. Am. J. Reprod. Immunol. 66, 84-89 (2011).
121. Barna, B. P. et al. A novel 1,25-dihydroxyvitamin D- activin A pathway in human alveolar macrophages is dysfunctional in patients with pulmonary alveolar proteinosis (PAP). Autoimmunity 42, 56-62 (2009).
122. Ahn, M. et al. Immunohistochemical study of arginase-1 in the spinal cords of Lewis rats with experimental autoimmune encephalomyelitis. Brain Res. 1453, 77-86 (2012).
123. Ihn, H. J. et al. Identification of Acvr2a as a Th17 cell- specific gene induced during Th17 differentiation. Biosci. Biotechnol. Biochem. 75, 2138-2141 (2011).
124. Voumvourakis, K. I., Antonelou, R., Kitsos, D. K., Stamboulis, E. & Tsiodras, S. TGF-β/BMPs: crucial crossroad in neural autoimmune disorders. Neurochem. Int. 59, 542-550 (2011).
125. Reier, P. J. & Houle, J. D. The glial scar: its bearing on axonal elongation and transplantation approaches to CNS repair. Adv. Neurol. 47, 87-138 (1988).
126. Bramlage, C. P. et al. Decrease in expression of bone morphogenetic proteins 4 and 5 in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Res. Ther. 8, R58 (2006).
127. Daans, M., Lories, R. J. & Luyten, F. P. Dynamic activation of bone morphogenetic protein signaling in collagen-induced arthritis supports their role in joint homeostasis and disease. Arthritis Res. Ther. 10, R115 (2008).
128. Lories, R. J., Derese, I., Ceuppens, J. L. & Luyten, F. P. Bone morphogenetic proteins 2 and 6, expressed in arthritic synovium, are regulated by proinflammatory cytokines and differentially modulate fibroblast-like synoviocyte apoptosis. Arthritis Rheum. 48, 2807-2818 (2003).
129. Marinova-Mutafchieva, L., Taylor, P., Funa, K., Maini, R. N. & Zvaifler, N. J. Mesenchymal cells expressing bone morphogenetic protein receptors are present in the rheumatoid arthritis joint. Arthritis Rheum. 43, 2046-2055 (2000).
130. Tang, Y. et al. Gene expression profile reveals abnormalities of multiple signaling pathways in mesenchymal stem cell derived from patients with systemic lupus erythematosus. Clin. Dev. Immunol. 2012, 826182 (2012).
131. Dieelberg, C. et al. Follistatin does not influence the course of Escherichia coli K1 sepsis in a mouse model. Shock 38, 615-619 (2012).
132. Wilms, H. et al. Regulation of activin A synthesis in microglial cells: pathophysiological implications for bacterial meningitis. J. Neurosci. Res. 88, 16-23 (2010).
133. Michel, U. et al. Increased activin levels in cerebrospinal fluid of rabbits with bacterial meningitis are associated with activation of microglia. J. Neurochem. 86, 238-245 (2003).
134. McCracken, K. W. et al. Modelling human development and disease in pluripotent stem-cell- derived gastric organoids. Nature 516, 400-404 (2014).
135. Shanmugam, N. K., Chen, K. & Cherayil, B. J. Commensal bacteria-induced interleukin 1β (IL-1β) secreted by macrophages up-regulates hepcidin expression in hepatocytes by activating the bone morphogenetic protein signaling pathway. J. Biol. Chem. 290, 30637-30647 (2015).
136. Letterio, J. J. et al. Autoimmunity associated with TGF-β1-deficiency in mice is dependent on MHC class II antigen expression. J. Clin. Invest. 98, 2109-2119 (1996).
137. Yaswen, L. et al. Autoimmune manifestations in the transforming growth factor-β1 knockout mouse. Blood 87, 1439-1445 (1996).
138. Bobr, A. et al. Autocrine/paracrine TGF-β1 inhibits Langerhans cell migration. Proc. Natl Acad. Sci. USA 109, 10492-10497 (2012).
139. Gutcher, I. et al. Autocrine transforming growth factor-β1 promotes in vivo Th17 cell differentiation. Immunity 34, 396-408 (2011).
140. Kaplan, D. H. et al. Autocrine/paracrine TGFβ1 is required for the development of epidermal Langerhans cells. J. Exp. Med. 204, 2545-2552 (2007).
141. Hall, B. E. et al. Conditional overexpression of TGF-β1 disrupts mouse salivary gland development and function. Lab. Invest. 90, 543-555 (2010).
142. De Paiva, C. S. et al. Disruption of TGF-β signaling improves ocular surface epithelial disease in experimental autoimmune keratoconjunctivitis sicca. PLoS ONE 6, e29017 (2011).
143. Du, W. et al. TGF-β signaling is required for the function of insulin-reactive T regulatory cells. J. Clin. Invest. 11 6, 1360-1370 (2006).
144. + regulatory T cells. J. Exp. Med. 201, 737-746 (2005).
145. Gate, D. et al. T-Cell TGF-β signaling abrogation restricts medulloblastoma progression. Proc. Natl Acad. Sci. USA 111, E3458-E3466 (2014).
146. + T cell expansion and lymphoproliferative disorder in mice. J. Immunol. 190, 6340-6350 (2013).
147. Laouar, Y., Sutterwala, F. S., Gorelik, L. & Flavell, R. A. Transforming growth factor-β controls T helper type 1 cell development through regulation of natural killer cell interferon-γ. Nat. Immunol. 6, 600-607 (2005).
148. Laouar, Y. et al. TGF-β signaling in dendritic cells is a prerequisite for the control of autoimmune encephalomyelitis. Proc. Natl Acad. Sci. USA 105, 10865-10870 (2008).
149. Raes, G., Beschin, A., Ghassabeh, G. H. & De Baetselier, P. Alternatively activated macrophages in protozoan infections. Curr. Opin. Immunol. 19, 454-459 (2007).
150. Robertson, A. K. et al. Disruption of TGF-β signaling in T cells accelerates atherosclerosis. J. Clin. Invest. 11 2, 1342-1350 (2003).
151. Zhang, W. et al. Deletion of interleukin-6 in mice with the dominant negative form of transforming growth factor β receptor II improves colitis but exacerbates autoimmune cholangitis. Hepatology 52, 215-222 (2010).
152. + T-cells when naive but promotes their survival and function once antigen experienced: a two-faced impact on autoimmunity. Diabetes 57, 2684-2692 (2008).
153. Ishigame, H. et al. Excessive Th1 responses due to the absence of TGF-β signaling cause autoimmune diabetes and dysregulated Treg cell homeostasis. Proc. Natl Acad. Sci. USA 110, 6961-6966 (2013).
154. Ouyang, W., Beckett, O., Ma, Q. & Li, M. O. Transforming growth factor-β signaling curbs thymic negative selection promoting regulatory T cell development. Immunity 32, 642-653 (2010).
155. Zhang, N. & Bevan, M. J. TGF-β signaling to T cells inhibits autoimmunity during lymphopenia-driven proliferation. Nat. Immunol. 13, 667-673 (2012).
156. Cazac, B. B. & Roes, J. TGF-β receptor controls B cell responsiveness and induction of IgA in vivo. Immunity 13, 443-451 (2000).
157. Lievens, D. et al. Abrogated transforming growth factor β receptor II (TGFβRII) signalling in dendritic cells promotes immune reactivity of T cells resulting in enhanced atherosclerosis. Eur. Heart J. 34, 3717-3727 (2013).
158. Ramalingam, R. et al. Dendritic cell-specific disruption of TGF-β receptor II leads to altered regulatory T cell phenotype and spontaneous multiorgan autoimmunity. J. Immunol. 189, 3878-3893 (2012).
159. Kim, B. G. et al. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature 441, 1015-1019 (2006).
160. + T cells. Nat. Immunol. 16, 1077-1084 (2015).
161. Wang, A. et al. Cutting edge: Smad2 and Smad4 regulate TGF-β-mediated Il9 gene expression via EZH2 displacement. J. Immunol. 191, 4908-4912 (2013).
162. Karlsson, G. et al. Smad4 is critical for self-renewal of hematopoietic stem cells. J. Exp. Med. 204, 467-474 (2007).
163. Singbrant, S. et al. Smad5 is dispensable for adult murine hematopoiesis. Blood 108, 3707-3712 (2006).
164. Fantini, M. C. et al. Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology 136, 1308-1316 (2009).
165. Ka, S. M. et al. Smad7 gene therapy ameliorates an autoimmune crescentic glomerulonephritis in mice. J. Am. Soc. Nephrol.18, 1777-1788 (2007).
166. Nakao, A. et al. Blockade of transforming growth factor β/Smad signaling in T cells by overexpression of Smad7 enhances antigen-induced airway inflammation and airway reactivity. J. Exp. Med. 192, 151-158 (2000).
167. Kleiter, I. et al. Smad7 in T cells drives T helper 1 responses in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain 133, 1067-1081 (2010).
168. Xia, Y. et al. Dragon (repulsive guidance molecule b) inhibits IL-6 expression in macrophages. J. Immunol. 186, 1369-1376 (2011).
169. Tsalavos, S. et al. Involvement of twisted gastrulation in T cell-independent plasma cell production. J. Immunol. 186, 6860-6870 (2011).
170. + double-positive cell. Cell Cycle 13, 324-333 (2014).
171. Yamawaki, K. et al. Adult-specific systemic over- expression reveals novel in vivo effects of the soluble forms of ActRIIA, ActRIIB and BMPRII. PLoS ONE 8, e78076 (2013).
172. Asano, Y. et al. Involvement of αvβ5 integrin-mediated activation of latent transforming growth factor β1 in autocrine transforming growth factor β signaling in systemic sclerosis fibroblasts. Arthritis Rheum. 52, 2897-2905 (2005).
173. Minagawa, S. et al. Selective targeting of TGF-β activation to treat fibroinflammatory airway disease. Sci. Transl Med. 6, 241ra279 (2014).
174. 6 inhibits tumor progression in vivo by a transforming growth factor-β-regulated mechanism. Cancer Res. 68, 561-570 (2008).
175. Border, W. A. et al. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 360, 361-364 (1992).
176. McMahon, G. A., Dignam, J. D. & Gentry, L. E. Structural characterization of the latent complex between transforming growth factor β1 and β1-latency- associated peptide. Biochem. J. 313, 343-351 (1996).
177. 2-macroglobulin. J. Biol. Chem. 262, 14090-14099 (1987).
178. Hardee, M. E. et al. Resistance of glioblastoma- initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β. Cancer Res. 72, 4119-4129 (2012).
179. 2 monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology 11 4, 1822-1830 (2007).
180. Trachtman, H. et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment- resistant primary focal segmental glomerulosclerosis. Kidney Int. 79, 1236-1243 (2011).
181. Zhong, Z. et al. Anti-transforming growth factor β receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin. Cancer Res. 16, 1191-1205 (2010).
182. George, J., Roulot, D., Koteliansky, V. E. & Bissell, D. M. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor β type II receptor: a potential new therapy for hepatic fibrosis. Proc. Natl Acad. Sci. USA 96, 12719-12724 (1999).
183. Juarez, P. et al. Soluble betaglycan reduces renal damage progression in db/db mice. Am. J. Physiol. Renal Physiol. 292, F321-F329 (2007).
184. Melisi, D. et al. LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol. Cancer Ther. 7, 829-840 (2008).
185. Petersen, M. et al. Oral administration of GW788388, an inhibitor of TGF-β type I and II receptor kinases, decreases renal fibrosis. Kidney Int. 73, 705-715 (2008).
186. Herbertz, S. et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-β signaling pathway. Drug Des. Devel. Ther. 9, 4479-4499 (2015).
187. Leung, S. Y. et al. Effect of transforming growth factor-β receptor I kinase inhibitor 2,4-disubstituted pteridine (SD-208) in chronic allergic airway inflammation and remodeling. J. Pharmacol. Exp. Ther. 319, 586-594 (2006).
188. Chen, J. L. et al. Development of novel activin-targeted therapeutics. Mol. Ther. 23, 434-444 (2015).
189. Nakamura, T. et al. Activin-binding protein from rat ovary is follistatin. Science 247, 836-838 (1990).
190. DePaolo, L. V., Bald, L. N. & Fendly, B. M. Passive immunoneutralization with a monoclonal antibody reveals a role for endogenous activin-B in mediating FSH hypersecretion during estrus and following ovariectomy of hypophysectomized, pituitary-grafted rats. Endocrinology 130, 1741-1743 (1992).
191. Hatsell, S. J. et al. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci. Transl Med. 7, 303ra137 (2015).
192. O'Connell, K. E. et al. The effects of an ActRIIb receptor Fc fusion protein ligand trap in juvenile simian immunodeficiency virus-infected rhesus macaques. FASEB J. 29, 1165-1175 (2015).
193. Raje, N. & Vallet, S. Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Curr. Opin. Mol. Ther. 12, 586-597 (2010).
194. Calpe, S. et al. Effective inhibition of bone morphogenetic protein function by highly specific llama-derived antibodies. Mol. Cancer Ther. 14, 2527-2540 (2015).
195. Gordon, M. S. et al. An open-label phase Ib dose- escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clin. Cancer Res. 20, 5918-5926 (2014).
196. Necchi, A. et al. PF-03446962, a fully-human monoclonal antibody against transforming growth- factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. Invest. New Drugs 32, 555-560 (2014).
197. Sakai, H. et al. Augmented autocrine bone morphogenic protein (BMP) 7 signaling increases the metastatic potential of mouse breast cancer cells. Clin. Exp. Metastasis 29, 327-338 (2012).
198. Andriopoulos, B. Jr et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat. Genet. 41, 482-487 (2009).
199. Castonguay, R. et al. Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth. J. Biol. Chem. 286, 30034-30046 (2011).
200. Hawinkels, L. J. et al. Activin receptor-like kinase 1 ligand trap reduces microvascular density and improves chemotherapy efficiency to various solid tumors. Clin. Cancer Res. 22, 96-106 (2016).
201. Steinbicker, A. U. et al. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood 11 7, 4915-4923 (2011).
202. Yamawaki, K. et al. The soluble form of BMPRIB is a novel therapeutic candidate for treating bone related disorders. Sci. Rep. 6, 18849 (2016).
203. Boergermann, J. H., Kopf, J., Yu, P. B. & Knaus, P. Dorsomorphin and LDN-193189 inhibit BMP- mediated Smad, 38 and Akt signalling in C2C12 cells. Int. J. Biochem. Cell Biol. 42, 1802-1807 (2010).
204. Sanvitale, C. E. et al. A new class of small molecule inhibitor of BMP signaling. PLoS ONE 8, e62721 (2013).
205. Tsugawa, D. et al. Specific activin receptor-like kinase 3 inhibitors enhance liver regeneration. J. Pharmacol. Exp. Ther. 351, 549-558 (2014).